1-2204

Please type a plus sign (+) inside this box → +

PTO/SB/21 (6-99)

Approved for use through 09/30/2000. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number. 10/723,434 Application Number November 26, 2003 TRANSMITTAL JAN 2 2004 Filing Date **FORM** First Named Inventor Pingyu Zhong T& TRA (to be used for all correspondence after initial filing) 1631 Group/Art Unit **Examiner Name** Unassigned Total Number of Pages in This Submission 26050-709.501 Attorney Docket Number ENCLOSURES (check all that apply) Assignment Papers After Allowance Communication Fee Transmittal Form (for an Application) to Group Appeal Communication to Board Fee Attached Drawing(s) of Appeals and Interferences Appeal Communication to Group Declaration For Utility or Design Amendment / Response (Appeal Notice, Brief, Reply Brief) Application Petition Routing Slip (PTO/SB/69) After Final Proprietary Information and Accompanying Petition Version with Markings Showing Petition to Convert to a Status Letter Changes Provisional Application Power of Attorney, Revocation Additional Enclosure(s) Extension of Time Request XChange of Correspondence Address (please identify below): Information Disclosure Statement Itemized return postcard, PTO Terminal Disclaimer form 1449 and copies of 3 non-Certified Copy of Priority patent references Sequence Listing/Diskette Document(s) Request for Refund Response to Missing Parts/ Incomplete Application Remarks Response to Missing Parts under 37 CFR 1.52 or 1.53 SIGNATURE OF APPLICANT, ATTORNEY OR AGENT Firm Shirley Chen, Reg. No. 44,608, WILSON SONSINI GOODRICH & ROSATI Individual name Signature Date Customer Number: 021971 CERTIFICATE OF EXPRESS MAILING I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. §1.10 on the date indicated below and addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on this date: 1/00/04 Express Mail Label EV 333 489 528 US Typed or printed name Tami O'Bryant January 00, 2004 Signature Date

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PATENT

Attorney Docket No. 26050-709.501

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application)	PATENT A	PPLICATION
Inventor(s): Zhong, Pingyu et al.)		
Application No.: 10/723,434)	Art Unit:	1631
Filed: November 26, 2003)	Examiner:	Unassigned
Title: HUMANIZED ANTIBODIES AGAINST VASCULAR ENDOTHELIAL GROWTH FACTOR) .		
	_)		

Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97

Sir:

Listed below or on an attached Form PTO-1449 is information known to applicant(s). A copy of each listed publication and U.S. and foreign patent, except for pending U.S. applications, is being submitted herewith, along with a concise explanation of information in a foreign language, if any, pursuant to 37 C.F.R. §1.97-1.98.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. If form PTO-1449 is enclosed, the Examiner is requested to initial and return it in accordance with MPEP §609.

Applicant(s) reserve(s) the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, material to patentability as defined in §1.56.

\boxtimes	This	stateme	nt qualifies under 37 C.F.R. §1.97, subsection (b) because (check all that apply):
	\boxtimes	(1)	It is being filed within 3 months of the application filing date and is other than a continued prosecution application under § 1.53(d) OR
		(2)	It is being filed within 3 months of entry of a national stage OR
	\boxtimes	(3)	It is being filed before the mail date of the first Office Action on the merits OR
		(4)	It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under § 1.114.
	the fination	ling dat nal stage t Office	97(c). If this statement is being filed after the latest of: (1) three months beyond the of a national application; (2) three months beyond the date of entry of the e as set forth in §1.491 in an international application; or (3) the mailing date of action on the merits, but before the mailing date of the earlier of a final office §1.113 or a notice of allowance under §1.311, then:
		a certi	ification as specified in §1.97(e) is provided below; or
			of \$180.00 as set forth in \$1.17(p) is authorized below, enclosed, or included the payment of other papers filed together with this statement.
	final (.97(d). If this statement is being filed after the mailing date of the earlier of action under §1.113 or a notice of allowance under §1.311, but before payment of then:
	A.	a certi	ification as specified in §1.97(e) is completed below; and
	В.		tion under 37 C.F.R. §1.97(d) requesting consideration of this statement is tted herewith; and
	C.		of \$130.00 as set forth in §1.17(i)(1) is authorized below, enclosed, or included the payment of other papers filed together with this statement.
	Copie herew		ach of the references listed on the attached Form PTO-1449 are enclosed
	Copie THA		erences listed on the attached Form PTO-1449 are enclosed herewith EXCEPT
		In vie refere (Seria	ew of the voluminous nature of references, and the likelihood that these nces are available to the Examiner in the file history of the parent application l No.), copies are not enclosed herewith.
			of the foregoing publications are not available to the Examiner, Applicant will

		accordance with 37 CFR 1.98 (a) application publication listed on t because this U.S. patent application	iments and non-patent literature are enclosed in 0(2). (The U.S. patents and each U.S. patent he attached Form PTO-1449 are not enclosed was filed after June 30, 2003 or this international stage under 35 USC §371 after June 30, 2003 (see a 37 CFR 1.98 (a)(2)(i).
	\boxtimes	There are no listed references which	are not in the English language.
		The relevance of those listed reference follows:	nces which are not in the English language is as
		Attached are copies of search repowhich are listed on the attached Subr	ort(s) from corresponding patent application(s), mission Under MPEP 609 D.
		-	lished pending patent applications which may be the attached Submission Under MPEP 609 D.
	fees of		nereby authorized to charge the above-referenced as or credit any overpayment associated with this 2415 (Docket No. 26050-709.501).
			Respectfully submitted,
			WILSON SONSINI GOODRICH & ROSATI
Dated:		1-16-04	By: Shirley Chen Pag No. 44 608
Palo A	ge Mill lto, CA 193-930	94304-1050	Reg. No. 44,608

Customer No. 021971





Approved for use through 10/31/2002. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. Department of Commerce

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

the paperwork reduction ret of 1779, no persons required		Complete if Known			
Substitute for form 1449A/PTO				Application No.	10/723,434
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	November 26, 2003		
		First Named Inventor	Pingyu Zhong		
		Art Unit	1631		
		Examiner Name	Unassigned		
Sheet	1	Of	1	Attorney Docket No.	26050-709.501

		OTHER PRIOR ART – NON PATENT RELATED DOCUMENTS	
Examiner	Cite	Include name of author (in CAPITAL LETTERS), title of the article (when appropriate), title of the Item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue	
Initials*	No.1	number(s) publisher city and/or country where published	T ²
		Chothia et al., Structural Determinants in the Sequences of Immunoglobulin Variable	
		Domain, J. Mol. Biol., Vol. 278, pp. 457-459, 1998.	<u>.</u>
		Iba et al., Changes in the Specificity of Antibodies Against Steroid Antigens by	
		Introduction of Mutations into Complementarity-Determining Regions of the V _H Domain,	ł
		Protein Engineering, Vol. 11, No. 5, pp. 361-370, 1998.	
		Knappik et al., Fully Synthetic Human Combinatorial Antibody Libraries (HuCAL)	
		Based on Modular Consensus Frameworks and CDRs Randomized with Trinucleotides, J.	
		Mol. Biol., Vol. 296, pp. 57-86, 2000.	
		•	
			<u> </u>
			-
			ļ
		•	ļ
.			1
			1
			
			1_
D D			
D11 11 (5)			<u> </u>
		DATE	
SIGNATU	KE	CONSIDERED	

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

EXAMINEN: Initial in reference considered, whether of not citation is in comormance with interpretation. Draw fine timough changing months of the communication to applicant.

1 Applicant's unique citation designation number (optional) 2 See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.